Annals of Oncology 13:989-990, 2002
© 2002 European Society for Medical Oncology
News |
Create your own organ?
| The first 10% of the full text of this article appears below. |
A team from the Children’s Hospital, Boston, MA, and Advanced Cell Technology, Worcester, MA, published results, in Nature Biotechnology July 2002, which may be of major interest. First they cloned an animal (a cow), which was to receive a transplant. They then allowed a cloned fetus (which will, however, also have some mitochondrial genetic material of the oocyte used for the clone) to develop in a ‘receiving mother’. The tissues obtained were then transplanted into the ‘donor’ (i.e. cloned) animal, and were not rejected. One such tissue was apparently an active kidney. In humans it would seem inconceivable to go to the level of fetal development used in these experiments, but . . .
Is Aventis following in the footsteps of Bristol-Myers Squibb?
All will remember that Bristol-Myers Squibb paid a sizeable sum (US$2 billion) for ImClone shares, shortly before the FDA rejected the
Another cytotoxic wins orphan drug status
Is Serono using illegal commercial tactics or are others trying to hurt Serono?
Cancer Research UK: a new mutual fund for the pharma industry?
The swing of the pendulum? Endostatin criticized in the lab, but of interest clinically?
Chernobyl 16 years later
Is the ‘human genome’ of Celera the genome of its past President?
Roche and Novartis? Or will it be GlaxoSmithKline and Bristol-Myers Squibb? And what about Pfizer?